AR020067A1 - USE AND COMPOSITION TO INDUCE AN ANTI-TUMORAL RESPONSE AGAINST A MELANOMA METASTASIS - Google Patents
USE AND COMPOSITION TO INDUCE AN ANTI-TUMORAL RESPONSE AGAINST A MELANOMA METASTASISInfo
- Publication number
- AR020067A1 AR020067A1 ARP990101625A ARP990101625A AR020067A1 AR 020067 A1 AR020067 A1 AR 020067A1 AR P990101625 A ARP990101625 A AR P990101625A AR P990101625 A ARP990101625 A AR P990101625A AR 020067 A1 AR020067 A1 AR 020067A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- melanoma
- composition
- membrane
- tumor response
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 8
- 230000006023 anti-tumor response Effects 0.000 title abstract 4
- 206010027476 Metastases Diseases 0.000 title abstract 3
- 230000009401 metastasis Effects 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 8
- 239000012528 membrane Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 208000021039 metastatic melanoma Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso y composicion para inducir una respuesta anti-tumoral contra una metástasis de melanoma mediante la administracion de una cantidad efectiva de unacomposicion que comprende al menos uno de los siguientes items: a) una célula de melanoma de un mamífero singeneica modificada con hapteno en una fase decrecimiento sustancialmente nulo; b) una membrana de célula de melanoma modificada con hapteno; c) un péptido extraído de dicha célula o membrana de célula demelanoma modificada con hapteno; y d) una célula T capaz de mediar una respuesta anti-tumoral como, por ejemplo, la regresion del melanoma. El melanomametastático tratado de acuerdo con la presente invencion incluye el melanoma metastático limitado al pulmon y es, preferentemente, una metástasis pulmonarpequena. La invencion se refiere además a una célula de melanoma, a una membrana extraída de célula de melanoma, a un péptido extraído de dicha célula omembrana, a una célula T que posee la propiedad de inducir una respuesta anti-tumoral, a una composicion que contiene dicha célula, membrana, péptido, célula To sus combinaciones, así como a métodos para su extraccion y preparacion.Use and composition to induce an anti-tumor response against a melanoma metastasis by administering an effective amount of a composition comprising at least one of the following items: a) a melanoma cell of a hapten modified syngeneic mammal in one phase substantially zero decrease; b) a hapten modified melanoma cell membrane; c) a peptide extracted from said hapten modified cell or membrane cell demelanoma; and d) a T cell capable of mediating an anti-tumor response such as, for example, melanoma regression. Melanoma metastatic treated in accordance with the present invention includes metastatic melanoma limited to lung and is preferably a small lung metastasis. The invention further relates to a melanoma cell, to a membrane extracted from melanoma cell, to a peptide extracted from said omembrane cell, to a T cell that has the property of inducing an anti-tumor response, to a composition containing said cell, membrane, peptide, cell To their combinations, as well as to methods for their extraction and preparation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8125698P | 1998-04-09 | 1998-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020067A1 true AR020067A1 (en) | 2002-04-10 |
Family
ID=22163059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101625A AR020067A1 (en) | 1998-04-09 | 1999-04-09 | USE AND COMPOSITION TO INDUCE AN ANTI-TUMORAL RESPONSE AGAINST A MELANOMA METASTASIS |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1067960A2 (en) |
| JP (1) | JP2003524583A (en) |
| CN (1) | CN1301174A (en) |
| AR (1) | AR020067A1 (en) |
| AU (1) | AU3482199A (en) |
| CA (1) | CA2327339A1 (en) |
| PL (1) | PL366240A1 (en) |
| WO (1) | WO1999052546A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1162996B1 (en) | 1999-03-16 | 2006-10-04 | Thomas Jefferson University | Hapten-conjugated mammalian cells and methods of making and using thereof |
| US7297330B2 (en) | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
| AU2003243485A1 (en) * | 2002-06-10 | 2003-12-22 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| FR3011850B1 (en) * | 2013-10-15 | 2018-04-06 | Cfl Biotech | THERAPEUTIC VACCINE AGAINST CANCER BASED ON IMMUNOGENIC STRESS PROTEINS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11507633A (en) * | 1995-06-07 | 1999-07-06 | トーマス・ジェファーソン・ユニバーシティ | Hapten-modified tumor cell extracts and methods for treating or screening for cancer |
| NZ330995A (en) * | 1996-10-04 | 2000-12-22 | Univ Jefferson | Generation of T cells mediating an immune response and use for treating cancer |
| PL342856A1 (en) * | 1998-02-17 | 2001-07-16 | Univ Jefferson | Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes |
-
1999
- 1999-04-09 PL PL99366240A patent/PL366240A1/en unknown
- 1999-04-09 JP JP2000543156A patent/JP2003524583A/en active Pending
- 1999-04-09 CA CA002327339A patent/CA2327339A1/en not_active Abandoned
- 1999-04-09 CN CN99806236A patent/CN1301174A/en active Pending
- 1999-04-09 AU AU34821/99A patent/AU3482199A/en not_active Abandoned
- 1999-04-09 AR ARP990101625A patent/AR020067A1/en unknown
- 1999-04-09 EP EP99916518A patent/EP1067960A2/en not_active Withdrawn
- 1999-04-09 WO PCT/US1999/007725 patent/WO1999052546A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999052546A3 (en) | 1999-12-16 |
| EP1067960A2 (en) | 2001-01-17 |
| CA2327339A1 (en) | 1999-10-21 |
| JP2003524583A (en) | 2003-08-19 |
| WO1999052546A2 (en) | 1999-10-21 |
| AU3482199A (en) | 1999-11-01 |
| CN1301174A (en) | 2001-06-27 |
| PL366240A1 (en) | 2005-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2154308T3 (en) | PHARMACEUTICAL OR COSMETIC FORMULATIONS CONTAINING CUMARINES AND PROANTOCIANIDINS. | |
| ES2104072T3 (en) | REDISTRIBUTION OF ORGANIC POLYCARBONATE COMPOSITIONS. | |
| ES2149276T3 (en) | IMIDAZO (4,5-C) PIRIDIN-4-AMINAS. | |
| CO5640082A2 (en) | COMPOUNDS DERIVED FROM FUSIONED HETEROCICLIC SUCCINIMIDA THAT ARE MODULATORS OF THE NUCLEAR HORMONE RECEPTOR FUNCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2052066T3 (en) | IMPROVEMENTS IN OR RELATED TO ORGANIC COMPOUNDS. | |
| DE69832699D1 (en) | CYCLIC ETHERIC VITAMIN D3 COMPOUNDS, 1ALFA (OH) 3-EPI-VITAMIN D3 COMPOUNDS AND ITS USES | |
| UY27069A1 (en) | ISOINDOLIN-1-ONA TYPE GLUCOCINASE ACTIVATORS | |
| CO6470858A2 (en) | IMPROVED RECONSTITUTED TENSIOACTIVE COMPOSITION CONTAINING ANALOGS OF THE TENSIOACTIVE PROTEIN B (SP-B) AND THE TENSIOACTIVE PROTEIN C (SP-C) | |
| ATE450246T1 (en) | STABILIZATION OF DYES IN COSMETIC AND DERMATOLOGICAL PREPARATIONS | |
| GT201000037A (en) | CYCLIC DEPSIPEPTIDES | |
| AR067980A1 (en) | PEPTIDES OF CDH3 AND AGENTS THAT UNDERSTAND THEM | |
| DK1276491T3 (en) | Tamandarin and didemnin analogues and methods for their preparation and use | |
| MX9207406A (en) | CONCENTRATOR / EXTRACTOR APPARATUS THAT HAS A HYDROPHOBIC MEMBRANE. | |
| DK1392335T3 (en) | Pharmaceutical and / or cosmetic composition for the treatment of local obesity and cellulite | |
| AR020067A1 (en) | USE AND COMPOSITION TO INDUCE AN ANTI-TUMORAL RESPONSE AGAINST A MELANOMA METASTASIS | |
| CO5680457A2 (en) | NOGO-A UNION MOLECULES AND PHARMACEUTICAL USE OF THE SAME | |
| GT200600106A (en) | ENDOPARASITICID AGENTS | |
| ECSP034531A (en) | SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA | |
| AR246160A1 (en) | Preservative for systems or products with an aqueous phase | |
| ES2130598T3 (en) | COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS. | |
| AR009819A1 (en) | PROTEASE INHIBITORS STABILIZED PROTEINS AND THEIR VARIABLES | |
| DK578887A (en) | antihypertensives | |
| MX9307203A (en) | STEROIDAL COMPOUNDS OF ACIL-3-CARBOXI-3,5-DIENO-17Ó AND 17ß-SUBSTITUTED. | |
| ES2084598T3 (en) | LIQUID DETERGENT COMPOSITIONS. | |
| ES2195156T3 (en) | COMPOSITIONS SIMILAR TO AZEOTROPOS OF 1,1,1,3,3-PENTAFLUOROPROPANE AND C1-C3 ALCOHOLS. |